KBC Group
AMLX icon

KBC Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

KBC Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26K Buy
+1,863
New +$26.2K ﹤0.01% 1817

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

KBC Group's AMLX Position: Q1 2026 in Review

KBC Group opened a new position in Amylyx Pharmaceuticals (AMLX) in Q1 2026: 1,863 shares worth $26K. The stake represents ﹤0.01% of the portfolio and ranks #1817 among its holdings.

171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • KBC Group held 1,863 shares of Amylyx Pharmaceuticals worth $26K as of Q1 2026.
  • Amylyx Pharmaceuticals was a new KBC Group position in Q1 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1817 holding.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.